Sollis Therapeutics is developing targeted non-opioid solutions to treat important pain conditions

Recent Posts

• Sollis Therapeutics Announces the First Patient Enrolled in a Phase 3 Clinical Trial of Clonidine Micropellet for Sciatica
• Dr. Gregory Fiore to Participate in a Panel on Pain Management: Alternatives to Opioids at BioOhio’s Neuroscience Discovery & Alternatives to Opioids Event
• Ohio State neurosurgeon’s startup could seek Third Frontier funds to reduce opioid prescriptions
• State awards money to support technological solutions to fight opiates
• Neurotechnology Innovations Translator (NIT) Announces Funding of up to $50 Million in Portfolio Company Sollis Therapeutics